EU approval of resmetirom: First therapy against fatty liver disease
The European Union has approved Resmetirom for the first time as a drug for the treatment of fatty liver disease with mild fibrosis. This milestone offers those affected a first drug therapy option. Significant research work on this topic took place at the Medical Faculty of the University of Duisburg-Essen and the University Hospital Essen.
Resmetiroma specifically activates the thyroid hormone receptor beta in liver cells, improves fat metabolism and avoids systemic side effects. The selective effect was demonstrated in the Collaborative Research Centre LOCOTACT, which showed that resmetiroma is efficiently absorbed in liver cells and binds more strongly to the beta receptor. Preclinical studies confirmed no effects on the heart or pituitary gland, but indicated a weakening of the effect with alcohol consumption.
The research work, which was awarded the von Basedow Prize 2025, marks a breakthrough in metabolic medicine. Organ-specific hormone modulation could open up new avenues in endocrinology.
Original Paper:
Editor: X-Press Journalistenbüro GbR
Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.
Most read
Interview with Dr. Jakob Adler on the EU AI Act: “The evaluation of the ever-increasing amounts of data will change our view of diseases” He is considered the father of the "Digital Competence and Artificial Intelligence (AI)" section of...- World’s first shunt operation with microsurgical robotic system at the UKSH At the University Medical Center Schleswig-Holstein (UKSH), Kiel Campus, a shunt operation was perfo...
- New findings on Long COVID: Messenger substances in nasal mucosa identified as the cause A research team from the Research Center Borstel, Kiel University, the University of Lübeck and the...
